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See Article, pages 1011–1019Non-alcoholic steatohepatitis (NASH) is estimated to affect about
1% of the European and North-American population. Longitudinal
studies reported that the histological parameters worsen in one
third of patients, which carries the risk of progression to cirrhosis
[1]. The most physiological therapy of NASH is physical exercise
and weight loss, and is especially indicated in overweight
patients with insulin resistance [2]. However, treatments based
on changes in lifestyle often fail, which provides the incentive
for the continued exploration of drug therapies. Glitazones,
which are PPAR-c agonists and insulin-sensitizers, have proven
promising in randomized clinical trials, but these drugs are asso-
ciated with weight gain. Moreover, the cardiovascular safety of
glitazones has been questioned [3].
In 1996, Laurin published a pilot study in which 24 NASH
patients were treated with 13–15 mg/kg/day of ursodeoxycholic
acid (UDCA) for 12 months [4]. The result was a signiﬁcant
decrease in mean serum concentrations of alkaline phosphatase
(8%), alanine transaminase (ALT) (30%), and gamma-glutamyl
transpeptidase (cGT) (45%), as well as a decrease in the histo-
logical grade of hepatic steatosis.
Why should UDCA be beneﬁcial in NASH? Three non-exclu-
sive mechanisms can explain the beneﬁts of UDCA. First, hepa-
tocyte apoptosis is a pathogenic feature of NASH [5] and UDCA
has well-known anti-apoptotic properties [6]. Second, TNF-a is
increased in NASH patients [7] and aggravates the insulin resis-
tance. UDCA has been reported to decrease serum TNF-a levels,
at least in patients with primary biliary cirrhosis [8]. The third
mechanism was deduced from experimental data, which
showed that the taurine-conjugated UDCA (TUDCA) decreases
endoplasmic reticulum stress [9] and that TUDCA improves
muscle and hepatic insulin sensitivity in obese individuals
[10].
When interpreted in light of this background, the results of a
randomized controlled trial of UDCA in NASH reported by Lindor
and colleagues were disappointing. Lindor enrolled 166 NASH
patients, who received either UDCA 13–15 mg/kg/d or placebo
for 2 years. Both groups achieved the same decrease in serumJournal of Hepatology 20
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E-mail address: jf.dufour@ikp.unibe.ch (J.-F. Dufour).ALT concentrations at the end of the study. Similarly, both groups
improved their degree of steatosis. Consequently, no measurable
beneﬁt could be attributable to UDCA. A smaller Swiss, random-
ized, controlled study reported no beneﬁt of UDCA over placebo
on histology in NASH patients [11]. There was a beneﬁcial effect
of UDCA on ALT in this trial, which was due to the absence of
improvement of serum ALT levels in the placebo arm.
These mostly negative results raise the possibility that UDCA
was not effective because its dosage was too low. Since the ben-
eﬁts of higher dosage of UDCA were reported for other diseases
[12,13], two trials with higher dosage were launched. This issue
of the Journal publishes the results of one study conducted by
Ratziu et al. [14]. One hundred and twenty-six patients with
biopsy-proven NASH and elevated ALT levels were randomized
to receive either high-dose UDCA (28–35 mg/kg/d) or placebo
for 1 year. The reduction of the mean ALT levels was signiﬁcantly
greater in the UDCA group than in the placebo group (see Table
1). High-dose UDCA was associated with a decrease in cGT and
a reduction of FibroTest measures, which has cGT as one of its
components and which was used as a surrogate marker for ﬁbro-
sis instead of histological analysis. Serum glucose concentrations
improved as did the insulin resistance (HOMA score) in the group
treated with high doses of UDCA. (see Table 1) The adinopectin
levels fell in both groups but the decrease was greater in the
control (22%) than in the high-dose UDCA group (5%, not
signiﬁcant).
In the second trial, Leuschner et al. assigned 185 patients with
biopsy-proven NASH to receive either high-dose UDCA (23–
28 mg/kg/d) or placebo for 18 months [15]. High-dose UDCA
failed to improve the histological parameters, the primary end-
point. The NASH activity score changed from 5.7 to 4.7 in the pla-
cebo group and from 5.6 to 4.3 in the high-dose UDCA group.
Only c-GT levels improved signiﬁcantly after the high-dose UDCA
for 18 months, whereas the ALT levels decreased in a comparable
way in both groups (see Table 1).
How do these two trials compare? Apart from the ethnic differ-
ences in the sample populations, the dose of UDCA was higher in
Ratziu’s trial than in Leuschner’s (28–35 vs. 23–28 mg, respec-
tively) and the duration of treatment was longer in Leuschner’s
study than in Ratziu’s (18 vs. 12 months, respectively). For the his-
tological inclusion criteria, Riatzu used the score elaborated by
Kleiner et al. [16], whereas Leuschner chose amodiﬁedBrunt score
[17]. Themean NASH activity score was higher in Leuschner’s trial11 vol. 54 j 856–858
Table 1. Serum glucose concentrations and insulin resistance (HOMA score) improve in the group treated with high doses of UDCA.
PLACEBO (N)
UDCA (N)
UDCA DOSE
INCLUSION-CRITERIA
DURATION
ENDPOINT HISTOLOGY
ENDPOINT ALT
ENDPOINT METABOLISM
OTHER ENDPOINTS
LINDOR 2004 [21]
86
80
13-15 mg/kg/d
Elevated ALT 1.5 fold for at 
least 3 months
Biopsy-proven NASH: >10% 
steatosis along with lobular 
necroinflammatory changes
2 years
Single pathologist blinded to 
the sequence of the biopsy 
and to the assigned treatment.  
Severity of fatty infiltration, 
necroinflammation, and fibrosis 
were graded (0-3)
Steatosis UDCA vs placebo:
Baseline mean 2.2 vs 2.1
change — 0.4 vs -0.3
in %  - 18% vs -14%
Degree of inflammation: 
Baseline mean 1.7 vs 1.8
change — 0 vs -0.1
Stage of fibrosis:
Baseline mean  1.5 vs  1.4
Change 0 vs 0
ALT, UDCA vs placebo
Baseline mean 105 vs 108
change -33 vs -32
in % -31% vs -29%  
BMI unchanged
DUFOUR 2006 [11]
15
18
12-15 mg/kg/d
Elevated ALT 1.5 fold for at 
least 6 months
Biopsy-proven NASH: >10% 
steatosis, hepatocellular injury 
(ballooning, dropout), lobular 
inflammation
2 years
Single pathologist blinded to 
the patient, sequence of the 
biopsies and assigned arm and 
scored the biopsies using the 
scoring system of Promrat et al. 
[22] 
Steatosis UDCA vs placebo: 
baseline mean 3.0 vs 2.9
change — 0.4 vs -0.4
in %  - 13% vs -14%,
Activity index, UDCA vs placebo: 
Baseline mean 6.3 vs 5.8
change — 0.8 vs -0.02 
Baseline mean  1.4 vs  1.0
change +0.3 vs +0.4
ALT, UDCA vs placebo
Baseline mean 111 vs 76
change -59 vs +1
in % -53 vs +1%  
BMI unchanged 
RATZIU 2010
61
55
28-35 mg/kg/d
Elevated ALT >50 IU/L on 3 
occasions in 12 months
Biopsy-proven NASH: >20% 
steatosis with hepatocyte 
ballooning and/or hepatic 
intralobular necoris) according 
to Kleiner et al. [16]
1 year
Not assessed
ALT, UDCA vs placebo
Baseline mean 109 vs 103
change -31 vs -2
in % -28% vs -2%  
BMI unchanged.
Glucose, UDCA vs placebo
Baseline mean 5.6 vs 5.5
Change -0.1 vs +0.2
In %  -2.2 % vs. +3.9 %
Insulin, UDCA vs placebo
Baseline mean 14 vs 15
change -11 vs -0
in % -19 % vs – 0.2 %
HOMA, UDCA vs placebo
Baseline mean 3.8 vs 3.5
Change -3.0 vs +3.7
in % -20 % vs. +6 %
γ-GT, UDCA vs placebo
Baseline mean 122 vs 126
Change -62 vs +24
In %  -51 % vs. +19 %
Fibrotest, UDCA vs placebo
Baseline mean 14 vs 15
change -1.5 vs +1.5
in % -11 % vs +10%
LEUSCHNER 2010 [15]
91
94
23-28 mg/kg/d
Elevated ALT 1.5 fold for  at 
least 3 months
Biopsy-proven NASH  
according to a modified Brunt 
Score [17]
1.5 years
Single pathologist blinded to 
the treatment scored the 
biopsies using modified Brunt 
score [17] and NASH activity 
score  [16]
Modified Brunt score, UDCA 
vs placebo
Baseline mean 7.0 vs 7.3
Change -1 vs -1
in % -14% vs. -14%
NASH activity score, UDCA 
vs placebo
Baseline mean 5.6 vs 5.7
Change -1.2 vs -1.0
in % -21 % vs. -18%
ALT, UDCA vs placebo
Baseline mean 100 vs 110
change -40 vs -38
in % -41% vs -35%  
BMI unchanged:
Glucose, UDCA vs placebo
Baseline mean 5.6 vs 5.6
Change -0.2 vs -0.1
In %  -3.4 % vs. -1.4 %  
γ-GT, UDCA vs placebo
Baseline mean 87 vs 91
Change -52 vs -17
In %  -60 % vs. +19 %
Stage of fibrosis, UDCA vs placebo:
In red, differences which were statistically signiﬁcant (p <0.05).
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than in Ratziu’s (5.6 vs. 5.15 in the high-dose UDCA arm and 5.7 vs.
4.88 in the placebo arm, respectively). The ALT improvement in
the placebo group of Leuschner’s trial stands in contrast to that
of Ratziu’s trial. Leuschner included patients with elevated ALT
levels documented over a period of 3 months whereas Ratziu
required documentation of elevated ALT on three occasions over
a period of 12 months. This may have excluded patients with ﬂuc-
tuating ALT levels. The fact that more diabetic patients were
enrolled in Ratziu’s trial than in Leuschner’s trail (39% in the UDCA
armand 25% in the placebo armvs. 11% and 12%, respectively)may
explain why Ratziu’s trial presented improved metabolic end-
points, albeit given in percentages. A comparison of the absolute
numbers (serum glucose decreased from 5.6 to 5.47 with high-
dose UDCA and increased from 5.5 to 5.7 with placebo) is less con-
vincing. It is noteworthy that a trend towards lower serumglucose
concentrations in the UDCA arm than the control arm was also
noted in Leuschner’s trial (5.9–5.71 (3%) vs. 5.6–5.52 (1.4%),
p = 0.193).
What message should be retained from these trials? The ﬁrst
message is that UDCA in monotherapy has no positive effect in
NASH with the usual dose, and has only marginal and perhaps
clinically irrelevant effects at a higher dose. But the story does
not end there for bile acids. In a randomized controlled trial, we
reported that vitamin E added to UDCA was better than UDCA
monotherapy [11]. Since vitamin E has shown impressive effects
in monotherapy in the treatment of NASH [18], a trial comparing
vitamin Emonotherapywith the vitamin E + UDCA combination is
warranted. Bile acids – but not UDCA – regulate metabolism by
binding to the nuclear hormone receptor farnesoid X and to a
transmembrane bile acid receptor, TGR5. Activation of farnesoid
X receptor improves insulin sensitivity and reduces circulating
glucose and lipids levels [19]. TGR5 is an important regulator of
glucose homeostasis and lipidmetabolism and its activation stim-
ulates energy expenditure and protects against obesity [20]. These
actions of bile acidsmimic those of lifestyle changes. The effects of
non-UDCA bile acids in NASH should now receive some of the
attention that we have, until now, reserved for UDCA.Conﬂict of interest
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